

Viktor GrÃ¼nwald

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8178566/publications.pdf>

Version: 2024-02-01

151
papers

6,469
citations

159585

30
h-index

71685

76
g-index

182
all docs

182
docs citations

182
times ranked

7793
citing authors

#	ARTICLE	IF	CITATIONS
1	A Prospectively Randomized Phase-II Trial of Axitinib versus Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma (BERAT Study). <i>Oncology Research and Treatment</i> , 2022, 45, 272-280.	1.2	0
2	Quality of Life of Patients with Head and Neck Cancer Receiving Cetuximab, Fluorouracil, Cisplatin Comparing to Cetuximab, Fluorouracil, Cisplatin, and Docetaxel within the CEFICID Trial. <i>Oncology Research and Treatment</i> , 2022, 45, 319-325.	1.2	1
3	Systemic therapy in metastatic renal cell carcinoma (mRCC): an evidence-based recommendation of the German interdisciplinary RCC guidelines group. <i>World Journal of Urology</i> , 2022, 40, 2381-2386.	2.2	3
4	Comprehensive analysis of serum chromogranin A and neuron-specific enolase levels in localized and castration-resistant prostate cancer. <i>BJU International</i> , 2021, 127, 44-55.	2.5	22
5	First-line pazopanib in intermediate- and poor-risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial. <i>International Journal of Cancer</i> , 2021, 148, 950-960.	5.1	5
6	Adding cetuximab to paclitaxel and carboplatin for first-line treatment of carcinoma of unknown primary (CUP): results of the Phase 2 AIO trial PACET-CUP. <i>British Journal of Cancer</i> , 2021, 124, 721-727.	6.4	5
7	The prognostic value of serum MMP-7 levels in prostate cancer patients who received docetaxel, abiraterone, or enzalutamide therapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 296.e11-296.e19.	1.6	6
8	Everolimus after failure of one prior VEGF-targeted therapy in metastatic renal cell carcinoma: Final results of the MARC-2 trial. <i>International Journal of Cancer</i> , 2021, 148, 1685-1694.	5.1	7
9	Phase 3 trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) monotherapy as a first-line treatment for patients (pts) with advanced renal cell carcinoma (RCC) (CLEAR study).. <i>Journal of Clinical Oncology</i> , 2021, 39, 269-269.	1.6	21
10	Patterns of progression in patients treated with nivolumab plus ipilimumab (NIVO+IPI) versus sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214.. <i>Journal of Clinical Oncology</i> , 2021, 39, 313-313.	1.6	8
11	Reply to E. Younger et al, V. Sharma et al, and M. Uchihara et al. <i>Journal of Clinical Oncology</i> , 2021, 39, 864-865.	1.6	0
12	What is next in second- and later-line treatment of metastatic renal cell carcinoma? review of the recent literature. <i>Current Opinion in Urology</i> , 2021, 31, 276-284.	1.8	7
13	Treatment of Angiosarcoma with Pazopanib and Paclitaxel: Results of the EVA (Evaluation of) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Cancers, 2021, 13, 1223.	3.7	15
14	Complete metabolic response in patients with advanced non-small cell lung cancer with prolonged response to immune checkpoint inhibitor therapy. , 2021, 9, e002262.		5
15	Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. <i>New England Journal of Medicine</i> , 2021, 384, 1289-1300.	27.0	956
16	Thrombospondin-2 and LDH Are Putative Predictive Biomarkers for Treatment with Everolimus in Second-Line Metastatic Clear Cell Renal Cell Carcinoma (MARC-2 Study). <i>Cancers</i> , 2021, 13, 2594.	3.7	2
17	Identification of a Prognostic Clinical Score for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Systemic Therapy Including Cetuximab. <i>Frontiers in Oncology</i> , 2021, 11, 635096.	2.8	3
18	Re: Nivolumab plus Cabozantinib Versus Sunitinib for Advanced Renal-cell Carcinoma. <i>European Urology</i> , 2021, 80, 256-257.	1.9	0

#	ARTICLE	IF	CITATIONS
19	PSMA-Ligand PET for Early Castration-Resistant Prostate Cancer: A Retrospective Single-Center Study. <i>Journal of Nuclear Medicine</i> , 2021, 62, 88-91.	5.0	21
20	Prognostic Impact of Lymphnode Metastases in Patients with Metastatic Renal Cell Carcinoma. <i>Kidney Cancer</i> , 2021, , 1-8.	0.4	0
21	Clinical Outcomes by Nephrectomy Status In METEOR, A Randomized Phase 3 Trial of Cabozantinib Versus Everolimus in Patients with Advanced Renal Cell Carcinoma. <i>Kidney Cancer</i> , 2020, 4, 29-39.	0.4	2
22	Real world data on the use of nivolumab and ipilimumab combination therapy or nivolumab monotherapy in the treatment of renal cell carcinoma: Interim results from the non-interventional study (NIS) NORA. <i>European Urology Open Science</i> , 2020, 19, e1107.	0.4	1
23	Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. , 2020, 8, e000891.		160
24	Are we ready to accept intermediate outcome measures in clinical cancer trials?. <i>Annals of Oncology</i> , 2020, 31, 973-975.	1.2	1
25	Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma. <i>ESMO Open</i> , 2020, 5, e000852.	4.5	18
26	Quality of life and added value of a tailored palliative care intervention in patients with soft tissue sarcoma undergoing treatment with trabectedin: a multicentre, cluster-randomised trial within the German Interdisciplinary Sarcoma Group (GISG). <i>BMJ Open</i> , 2020, 10, e035546.	1.9	6
27	Randomized Comparison of Pazopanib and Doxorubicin as First-Line Treatment in Patients With Metastatic Soft Tissue Sarcoma Age 60 Years or Older: Results of a German Intergroup Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 3555-3564.	1.6	56
28	Systemic treatment of advanced/metastatic renal cell carcinoma in the context of SARS-CoV-2 pandemic: recommendations from the interdisciplinary working group for renal tumors (IAG-N). <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 3075-3078.	2.5	4
29	1669TiP A non-randomized, open-label phase II trial evaluating efficacy and feasibility of combined treatment with trabectedin and nivolumab in patients with metastatic or inoperable soft tissue sarcomas (STS) after failure of an anthracycline-containing regimen. <i>Annals of Oncology</i> , 2020, 31, S991.	1.2	1
30	718P A phase II study of patients with advanced or metastatic renal cell carcinoma (mRCC) receiving pazopanib after previous checkpoint inhibitor treatment. <i>Annals of Oncology</i> , 2020, 31, S564.	1.2	6
31	A Randomized Phase IIa Trial with Temsirolimus versus Sunitinib in Advanced Non-Clear Cell Renal Cell Carcinoma: An Intergroup Study of the CESAR Central European Society for Anticancer Drug Research-EWIV and the Interdisciplinary Working Group on Renal Cell Cancer (IAGN) of the German Cancer Society. <i>Oncology Research and Treatment</i> , 2020, 43, 333-339.	1.2	20
32	Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events. <i>British Journal of Cancer</i> , 2020, 123, 898-904.	6.4	36
33	New First Line Treatment Options of Clear Cell Renal Cell Cancer Patients with PD-1 or PD-L1 Immune-Checkpoint Inhibitor-Based Combination Therapies. <i>Journal of Clinical Medicine</i> , 2020, 9, 565.	2.4	35
34	Global treatment patterns and outcomes among patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results of the GLANCE H&N study. <i>Oral Oncology</i> , 2020, 102, 104526.	1.5	37
35	Radiological Monitoring of Modern Immunotherapy: A Novel Challenge for Interdisciplinary Patient Care. <i>RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren</i> , 2020, 192, 235-245.	1.3	7
36	A randomized phase II trial comparing switch to nivolumab with TKI continuation after 12 weeks of TKI induction therapy in metastatic renal cell carcinoma patients (NIVOSWITCH).. <i>Journal of Clinical Oncology</i> , 2020, 38, 678-678.	1.6	2

#	ARTICLE	IF	CITATIONS
37	CaboPoint, a phase II, open-label study of cabozantinib as second-line therapy for patients with clear cell metastatic renal cell carcinoma (RCC), whose disease progressed after therapy with checkpoint inhibitors (CPIs).. Journal of Clinical Oncology, 2020, 38, TPS772-TPS772.	1.6	2
38	Hepatic toxicity during regorafenib treatment in patients with metastatic gastrointestinal stromal tumors. Molecular and Clinical Oncology, 2020, 13, 1-1.	1.0	7
39	A phase III, randomized, placebo-controlled trial of nivolumab or nivolumab plus ipilimumab in patients with localized renal cell carcinoma at high-risk of relapse after radical or partial nephrectomy (CheckMate 914).. Journal of Clinical Oncology, 2020, 38, TPS5099-TPS5099.	1.6	17
40	Sequential treatment with pazopanib followed by nivolumab in patients with renal cell carcinoma: Updated interim results of the non-interventional study PAZOREAL.. Journal of Clinical Oncology, 2020, 38, e17075-e17075.	1.6	1
41	Survival in metastatic renal cell carcinoma (mRCC) patients over two decades: Does age matter?. Journal of Clinical Oncology, 2020, 38, e17103-e17103.	1.6	0
42	Retrospective comparison of the different immune combinations in metastatic renal cell carcinoma. Annals of Translational Medicine, 2020, 8, 839-839.	1.7	0
43	Axitinib plus Immuncheckpoint-Inhibitor: evidenz- und expertenbasierte Konsensusempfehlungen fÃ¼r die Behandlungsoptimierung und das Management von therapieassoziierten Nebenwirkungen. Karger Kompass Onkologie, 2020, 7, 180-189.	0.0	0
44	Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncology, The, 2019, 20, 1370-1385.	10.7	594
45	Real world evidence in renal cell carcinoma: A national, prospective, non-interventional study of nivolumab in patients with advanced renal cell carcinoma after prior therapy (NORA). European Urology Supplements, 2019, 18, e1841.	0.1	0
46	Association between depth of response and overall survival: Exploratory analysis in patients with previously untreated advanced renal cell carcinoma (aRCC) in CheckMate 214. Annals of Oncology, 2019, 30, v382-v383.	1.2	9
47	A phase II trial of TKI induction followed by a randomized comparison between nivolumab or TKI continuation in renal cell carcinoma (NIVOSWITCH). Annals of Oncology, 2019, 30, v388.	1.2	0
48	Advanced renal cell carcinoma: First results from the prospective research platform CARAT for patients with mRCC in Germany. Annals of Oncology, 2019, 30, v392.	1.2	0
49	Soft tissue sarcomas express a distinct mRNA immune profile. Annals of Oncology, 2019, 30, v702.	1.2	0
50	Cetuximab, fluorouracil and cisplatin with or without docetaxel for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CeFCiD): an open-label phase II randomised trial (AIO/IAG-KHT trial 1108). European Journal of Cancer, 2019, 122, 53-60.	2.8	16
51	Renal cell carcinoma in kidney transplant recipients: descriptive analysis and overview of a major German transplant center. Future Oncology, 2019, 15, 3739-3750.	2.4	5
52	Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale. Future Oncology, 2019, 15, 929-941.	2.4	40
53	Sarcoid-Like Lesions Mimicking Pulmonary Metastasis: A Case Series and Review of the Literature. Oncology Research and Treatment, 2019, 42, 382-386.	1.2	1
54	COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2019, 17, 425-435.e4.	1.9	11

#	ARTICLE	IF	CITATIONS
55	Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2019, 30, 706-720.	1.2	750
56	The Current and Evolving Landscape of First-Line Treatments for Advanced Renal Cell Carcinoma. <i>Oncologist</i> , 2019, 24, 338-348.	3.7	34
57	Re: Preliminary Results for Avelumab Plus Axitinib as First-Line Therapy in Patients with Advanced Clear-cell Renal-cell Carcinoma (JAVELIN Renal 100): An Open-label, Dose-finding and Dose-expansion, Phase 1b Trial. <i>European Urology</i> , 2019, 75, 697-698.	1.9	2
58	Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 297-310.	10.7	207
59	Paclitaxel/carboplatin with or without cetuximab for treatment of carcinoma with unknown primary (PACET-CUP): Results of a multi-center randomized phase II AIO trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4120-4120.	1.6	2
60	Sequential treatment with pazopanib (PAZO) followed by nivolumab (NIVO) in patients with advanced or metastatic renal cell carcinoma (mRCC): Third interim results of the non-interventional study PAZOREAL.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4574-4574.	1.6	2
61	Translational study associated to a phase II study evaluating the activity of pazopanib in patients (pts) with advanced/metastatic liposarcoma (LPS): A joint Spanish Sarcoma Group (GEIS) and German Interdisciplinary Sarcoma Group (GISG) study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 11067-11067.	1.6	0
62	A prospective, open label, multicenter, randomized phase II trial: Sequential therapy with bevacizumab, RAD001 (everolimus) and axitinib in metastatic renal cell carcinoma (mRCC) (BERAT study).. <i>Journal of Clinical Oncology</i> , 2019, 37, e16097-e16097.	1.6	0
63	A randomized phase II study of durvalumab and tremelimumab compared to doxorubicin in patients with advanced or metastatic soft tissue sarcoma (MEDISARC, AIO-STS 0415).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS11075-TPS11075.	1.6	2
64	Aiming for complete responses in renal-cell carcinoma. <i>Lancet Oncology</i> , The, 2018, 19, 428-429.	10.7	0
65	Early tumor shrinkage is independently associated with improved overall survival among patients with metastatic renal cell carcinoma: a validation study using the COMPARZ cohort. <i>World Journal of Urology</i> , 2018, 36, 1423-1429.	2.2	7
66	Collection of real-world data on nivolumab's effectiveness in renal cell carcinoma: rationale for an observational study. <i>Future Oncology</i> , 2018, 14, 1023-1034.	2.4	1
67	The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 â€œCREATEâ€™. <i>European Journal of Cancer</i> , 2018, 94, 156-167.	2.8	35
68	Pre- and Postoperative Chemotherapy in Localized Extremity Soft Tissue Sarcoma: A European Organization for Research and Treatment of Cancer Expert Survey. <i>Oncologist</i> , 2018, 23, 461-467.	3.7	27
69	Quality of life in patients with soft tissue sarcoma undergoing palliative treatment: A multicenter, cluster-randomized trial within the Germany Interdisciplinary Sarcoma Group (GISG-12). <i>Annals of Oncology</i> , 2018, 29, viii578.	1.2	1
70	Characterization of response to nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with previously untreated advanced renal cell carcinoma (arcc): Checkmate 214. <i>Annals of Oncology</i> , 2018, 29, viii309-viii310.	1.2	4
71	Health-related quality of life (HR-QoL) in elderly soft tissue sarcoma (STS) patients from the randomized phase II EPAZ study comparing pazopanib (PAZ) and doxorubicin (DOX) in first line. <i>Annals of Oncology</i> , 2018, 29, viii577.	1.2	0
72	A phase III, randomized, placebo-controlled trial of adjuvant nivolumab plus ipilimumab in patients (pts) with localized renal cell carcinoma (RCC) who are at high risk of relapse after radical or partial nephrectomy (CheckMate 914). <i>Annals of Oncology</i> , 2018, 29, viii330.	1.2	3

#	ARTICLE	IF	CITATIONS
73	Molecular Imaging in Oncology Using Positron Emission Tomography. Deutsches Ärzblatt International, 2018, 115, 175-181.	0.9	27
74	Metastatic Liposarcoma: A Case of Partial Remission with Eribulin in Late Treatment Lines. Journal of Clinical Case Reports, 2018, 08, .	0.0	0
75	Efficacy and safety of pazopanib in patients with advanced and/or metastatic renal cell carcinoma (mRCC) after previous checkpoint inhibitor treatment. European Urology Supplements, 2018, 17, e2957.	0.1	0
76	Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1–3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with <i>FGFR3</i> Alterations. Cancer Discovery, 2018, 8, 812-821.	9.4	206
77	The role of nephrectomy in metastatic renal cell carcinoma. Nature Reviews Nephrology, 2018, 14, 601-602.	9.6	2
78	An interdisciplinary consensus on the management of bone metastases from renal cell carcinoma. Nature Reviews Urology, 2018, 15, 511-521.	3.8	61
79	Randomized comparison of pazopanib (PAZ) and doxorubicin (DOX) in the first line treatment of metastatic soft tissue sarcoma (STS) in elderly patients (pts): Results of a phase II study (EPAZ).. Journal of Clinical Oncology, 2018, 36, 11506-11506.	1.6	11
80	Effect of crizotinib on disease control in patient with advanced papillary renal cell carcinoma type 1 with MET mutations or amplification: Final results of EORTC 90101 CREATE.. Journal of Clinical Oncology, 2018, 36, 580-580.	1.6	1
81	A phase 3 trial to compare efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of patients with metastatic renal cell carcinoma.. Journal of Clinical Oncology, 2018, 36, TPS706-TPS706.	1.6	8
82	Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma. Current Oncology Reports, 2017, 19, 14.	4.0	46
83	Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy: a subgroup analysis of the European Organisation for Research and Treatment of Cancer 62012 study. Acta Oncologica, 2017, 56, 1013-1020.	1.8	29
84	CT patterns of organizing pneumonia in patients treated with VEGF/mTOR inhibitors for metastatic renal cell cancer: an observational study. Acta Radiologica Open, 2017, 6, 205846011769421.	0.6	2
85	Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 “CREATE™. Annals of Oncology, 2017, 28, 3000-3008.	1.2	70
86	Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial. European Journal of Cancer, 2017, 87, 147-163.	2.8	108
87	Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. Lancet Oncology, The, 2017, 18, 1104-1115.	10.7	325
88	An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PATients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG). Annals of Oncology, 2017, 28, 2399-2408.	1.2	274
89	Therapy of Treatment-Related Hypertension in Metastatic Renal-Cell Cancer Patients Receiving Sunitinib. Clinical Genitourinary Cancer, 2017, 15, 280-290.e3.	1.9	6
90	Interim results from PAZOREAL: A non-interventional study to assess effectiveness and safety of pazopanib and everolimus in the changing mRCC treatment landscape. Annals of Oncology, 2017, 28, v318-v319.	1.2	0

#	ARTICLE	IF	CITATIONS
91	Predictive Factors for Second-Line Therapy in Metastatic Renal Cell Carcinoma: A Retrospective Analysis. <i>Journal of Kidney Cancer and VHL</i> , 2017, 4, 8-15.	1.0	7
92	Clinical outcomes by nephrectomy status in METEOR, a randomized phase 3 trial of cabozantinib (cabo) vs everolimus (eve) in patients (pts) with advanced renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 4570-4570.	1.6	1
93	The Diagnosis, Treatment, and Follow-up of Renal Cell Carcinoma. <i>Deutsches Arzteblatt International</i> , 2016, 113, 590-6.	0.9	21
94	A phase II trial comparing pazopanib with doxorubicin as first-line treatment in elderly patients with metastatic or advanced soft tissue sarcoma (EPAZ): study protocol for a randomized controlled trial. <i>Trials</i> , 2016, 17, 312.	1.6	28
95	Overall Survival Analysis From a Randomized Phase II Study of Axitinib With or Without Dose Titration in First-Line Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 499-503.	1.9	39
96	Radiotherapy for isolated lymph node metastases in patients with locally advanced prostate cancer after primary therapy. <i>World Journal of Urology</i> , 2016, 34, 1239-1245.	2.2	3
97	Does the onset of bone metastasis in sunitinib-treated renal cell carcinoma patients impact the overall survival?. <i>World Journal of Urology</i> , 2016, 34, 909-915.	2.2	5
98	Do programmed death 1 (PD-1) and its ligand (PD-L1) play a role in patients with non-clear cell renal cell carcinoma?. <i>Medical Oncology</i> , 2016, 33, 59.	2.5	22
99	Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis. <i>European Journal of Cancer</i> , 2016, 69, 226-235.	2.8	65
100	Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy. <i>Cancer Treatment Reviews</i> , 2016, 50, 109-117.	7.7	64
101	Absence of progression, not extent of tumour shrinkage, defines prognosis in soft-tissue sarcoma – An analysis of the EORTC 62012 study of the EORTC STBSG. <i>European Journal of Cancer</i> , 2016, 64, 44-51.	2.8	31
102	Vorinostat in refractory soft tissue sarcomas – Results of a multi-centre phase II trial of the German Soft Tissue Sarcoma and Bone Tumour Working Group (AIO). <i>European Journal of Cancer</i> , 2016, 64, 74-82.	2.8	28
103	Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2016, 70, 1006-1015.	1.9	23
104	Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 994-1003.	10.7	194
105	Intratumoral expression of programmed death ligand 1 (PD-L1) in patients with clear cell renal cell carcinoma (ccRCC). <i>Medical Oncology</i> , 2016, 33, 80.	2.5	32
106	Proof of principle for bevacizumab activity in desmoid-type fibromatosis. <i>Clinical Sarcoma Research</i> , 2016, 6, 5.	2.3	3
107	Checkpoint Blockade - a New Treatment Paradigm in Renal Cell Carcinoma. <i>Oncology Research and Treatment</i> , 2016, 39, 353-358.	1.2	6
108	Efficacy and safety of gemcitabine, oxaliplatin, and paclitaxel in cisplatin-refractory germ cell cancer in routine care – Registry data from an outcomes research project of the German Testicular Cancer Study Group. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 168.e21-168.e28.	1.6	25

#	ARTICLE	IF	CITATIONS
109	Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. <i>Cancer Treatment Reviews</i> , 2016, 45, 7-18.	7.7	354
110	2598 Early tumor shrinkage (eTS) - a novel endpoint for clinical studies in metastatic renal cell carcinoma (mRCC). <i>European Journal of Cancer</i> , 2015, 51, S510-S511.	2.8	1
111	T-cell checkpoint inhibitors in metastatic renal cell carcinoma. <i>Current Opinion in Urology</i> , 2015, 25, 411-415.	1.8	7
112	Axitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinoma. <i>Annals of Oncology</i> , 2015, 26, 1372-1377.	1.2	69
113	TEMHEAD: a single-arm multicentre phase II study of temsirolimus in platin- and cetuximab refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) of the German SCCHN Group (AIO). <i>Annals of Oncology</i> , 2015, 26, 561-567.	1.2	55
114	Baseline caspase activity predicts progression free survival of temsirolimus-treated head neck cancer patients. <i>European Journal of Cancer</i> , 2015, 51, 1596-1602.	2.8	9
115	Role of immunohistochemistry and fluorescence in-situ hybridization (FISH) in the diagnosis of spindle and round cell tumors of the kidney. <i>Journal of the Egyptian National Cancer Institute</i> , 2015, 27, 173-178.	1.5	2
116	Depth of Remission is a Prognostic Factor for Survival in Patients with Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2015, 67, 952-958.	1.9	61
117	Algorithms in the First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma—Analysis Using Diagnostic Nodes. <i>Oncologist</i> , 2015, 20, 1028-1035.	3.7	23
118	Overall survival analysis from a randomized phase II study of axitinib with or without dose titration for first-line metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4545-4545.	1.6	1
119	Efficacy and safety of gemcitabine, oxaliplatin and paclitaxel (GOP) in cisplatin-refractory germ cell tumors in routine care: Registry data from an outcomes research project.. <i>Journal of Clinical Oncology</i> , 2015, 33, e15570-e15570.	1.6	0
120	Synovial Sarcoma of the Kidney in a Young Patient with a Review of the Literature. <i>Rare Tumors</i> , 2014, 6, 83-85.	0.6	8
121	Phase II Results of Dovitinib (TKI258) in Patients with Metastatic Renal Cell Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 3012-3022.	7.0	48
122	Categories of response to first line vascular endothelial growth factor receptor targeted therapy and overall survival in patients with metastatic renal cell carcinoma. <i>European Journal of Cancer</i> , 2014, 50, 563-569.	2.8	20
123	Controversies in renal cell carcinoma: Treatment choice after progression on vascular endothelial growth factor-targeted therapy. <i>European Journal of Cancer</i> , 2014, 50, 1321-1329.	2.8	31
124	Systemic therapy of renal cell carcinoma. <i>World Journal of Urology</i> , 2014, 32, 1-1.	2.2	4
125	Interstitial lung disease during targeted therapy in metastatic renal cell carcinoma: a case series from three centres. <i>Medical Oncology</i> , 2014, 31, 147.	2.5	10
126	Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 286-296.	10.7	239

#	ARTICLE	IF	CITATIONS
127	Cetuximab (C), Fluorouracil (F) and Cisplatin (P) Alone or with Docetaxel (D) for Recurrent/Metastatic (Rm) Head and Neck Cancer (Hnscc). Final Analysis of Aio Trial # 1108 - Cefcid.. Annals of Oncology, 2014, 25, iv340.	1.2	17
128	Final results of patients with metastatic renal cell carcinoma treated with MGN1601 in the ASET study.. Journal of Clinical Oncology, 2014, 32, e15590-e15590.	1.6	5
129	DNA Methylation Biomarkers Predict Progression-Free and Overall Survival of Metastatic Renal Cell Cancer (mRCC) Treated with Antiangiogenic Therapies. PLoS ONE, 2014, 9, e91440.	2.5	42
130	Late onset of bone metastases as a prognostic parameter in metastatic renal cell cancer (mRCC): A single-center experience in 82 mRCC patients treated with sunitinib.. Journal of Clinical Oncology, 2014, 32, 523-523.	1.6	0
131	Practical Management of Everolimus-Related Toxicities in Patients with Advanced Solid Tumors. Onkologie, 2013, 36, 295-302.	0.8	29
132	The progression free survival-plateau with vascular endothelial growth factor receptor inhibitors â€œ Is there more to come?. European Journal of Cancer, 2013, 49, 2504-2511.	2.8	10
133	Interstitial lung diseases during treatment with sunitinib or mTOR inhibitors in metastatic renal cell carcinoma.. Journal of Clinical Oncology, 2013, 31, 420-420.	1.6	13
134	Prognostic value of free testosterone (FT) levels during salvage chemotherapy with carboplatin plus weekly docetaxel in metastatic castration- and docetaxel-resistant prostate cancer (mDRPC).. Journal of Clinical Oncology, 2013, 31, 152-152.	1.6	0
135	Effectiveness of abiraterone as salvage therapy in patients with docetaxel- and castration-resistant prostate cancer (mDCPC) that progressed during second-line chemotherapy with carboplatin plus weekly docetaxel (DC).. Journal of Clinical Oncology, 2013, 31, e16064-e16064.	1.6	0
136	An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. European Journal of Cancer, 2012, 48, 324-332.	2.8	84
137	Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment. OncoTargets and Therapy, 2012, 5, 111.	2.0	22
138	Axitinib for first-line metastatic renal cell carcinoma (mRCC): Overall efficacy and pharmacokinetic (PK) analyses from a randomized phase II study.. Journal of Clinical Oncology, 2012, 30, 4503-4503.	1.6	17
139	MARC-2: An open-label trial to characterize patients with metastatic renal cell carcinoma (mRCC) treated with everolimus after failure of the first VEGFR-TKI therapy.. Journal of Clinical Oncology, 2012, 30, 467-467.	1.6	1
140	Response of renal lesions during systemic treatment with sunitinib in patients with metastatic renal cell carcinoma: a single center experience with 14 patients. World Journal of Urology, 2011, 29, 355-360.	2.2	9
141	Efficacy of Sunitinib Re-Exposure after Failure of an mTOR Inhibitor in Patients with Metastatic RCC. Onkologie, 2011, 34, 310-314.	0.8	36
142	Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies. British Journal of Cancer, 2011, 105, 1635-1639.	6.4	29
143	Everolimus in patients with metastatic renal cell carcinoma (mRCC) who are intolerant of or have progressed after prior vascular endothelial growth factor receptorâ€™tyrosine kinase inhibitor (VEGFr-TKI) therapy: An international expanded access program (EAP).. Journal of Clinical Oncology, 2011, 29, 314-314.	1.6	1
144	Treatment with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma is associated with drug-induced hyperparathyroidism: a single center experience in 59 patients. World Journal of Urology, 2010, 28, 311-317.	2.2	2

#	ARTICLE	IF	CITATIONS
145	Management of sunitinib-related adverse events: an evidence- and expert-based consensus approach. World Journal of Urology, 2010, 28, 343-351.	2.2	20
146	Recall pneumonitis during systemic treatment with sunitinib. Annals of Oncology, 2010, 21, 2119-2120.	1.2	20
147	Can Tyrosine Kinase Inhibitors be Discontinued in Patients with Metastatic Renal Cell Carcinoma and a Complete Response to Treatment? A Multicentre, Retrospective Analysis. European Urology, 2009, 55, 1430-1439.	1.9	87
148	Patient-reported outcomes in a randomized trial of everolimus with metastatic renal cell carcinoma patients. Journal of Clinical Oncology, 2009, 27, e17516-e17516.	1.6	3
149	High response to docetaxel (D)/carboplatin (C) based chemotherapy as salvage therapy in patients with docetaxel-resistant metastatic hormone-refractory prostate cancer (HRPC). Journal of Clinical Oncology, 2009, 27, e16041-e16041.	1.6	0
150	Managing Side Effects of Angiogenesis Inhibitors in Renal Cell Carcinoma. Oncology Research and Treatment, 2007, 30, 519-524.	1.2	24
151	Acral Necrosis after Inadequate Excessive Administration of Bleomycin in a Testicular Cancer Patient. Oncology Research and Treatment, 2005, 28, 41-43.	1.2	1